OBJECTIVE: This open-label clinical trial primarily examined the safety and tolerability of ketamine treatment in patients with mild cognitive impairment and Major Depressive Disorder (MCI-D). Preliminary efficacy was also explored. METHODS: The trial was conducted between November 2023 and March 2025. Patients with MCI-D and moderate to severe symptom levels of depression received a single...
medRxivFebruary 7, 2025Andrew G. Breithaupt, Georges Naasan, Suzanne M. Shdo et al.
preprint
Abstract Psychosis is a common symptom in neurodegenerative diseases that contributes to significant patient and caregiver burden. While neuroimaging studies have implicated various brain regions in psychosis, findings have been inconsistent across different disease entities and psychosis subtypes. This study aimed to identify structural neuroanatomic changes associated with specific patterns...